Ruedi Aebersold is one of the pioneers in proteomics. He is known for developing methods that have found wide application in analytical protein chemistry like a new class of reagents termed Isotope Coded Affinity Tag (ICAT) reagents used in quantitative mass spectrometry. Ruedi and his team of researchers use the protein profiles determined by this method to differentiate cells in different states, such as noncancerous versus cancerous cells, and to systematically study how cells respond to external stimuli. These "snapshot" profiles indicate which cells contain abnormal levels of certain proteins. This is expected to lead to new diagnostic markers for disease and to a more complete understanding of the biochemical processes that control and constitute cell physiology. Ruedi serves on the Scientific Advisory Committees of numerous academic and private sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics. Ruedi obtained his Ph.D. in Cellular Biology at the Biocenter of the University of Basel in 1983. Ruedi co-founded the Institute for Systems Biology in Seattle before relocating to ETH in Zurich.

Dr. J.J.M. Bergeron has made discoveries in protein maturation, trafficking and function and has applied proteomic techniques to study the biochemistry of specific cellular compartments including elements of the secretory apparatus.

Dr. Bergeron is a Co-Founder, Scientific Advisor and past CSO to Caprion Pharmaceuticals. He is a Fellow of the Royal Society of Canada, recipient of the McLaughlin Gold Medal from this Society for important research of sustained excellence in any branch of medical sciences. He has given the David L. Thomson Lecture at McGill University, the Theo Hoffmann Biochemistry Lecture at the University of Toronto, the Nan Qiang Lecture at Xiamen University in China and Raymond Chiu Memorial Lecture at Albert Einstein College of Medicine. He is the recipient of Canadian National Proteomics Network 2010 Award for Outstanding Contribution and Leadership to the Canadian Proteomics Community. He is the past Chair of Anatomy and Cell Biology at McGill University and the Robert Reford Professor.

He was the Chair of the Scientific and Organizing Committees of past HUPO World Congresses, a member of its council and past Co-Chair of its International Liver Proteome Project, Chair of the Mouse Models of Human Disease efforts in proteomics and President of Human Proteome Organisation from 2003-2006. He was the chair of the HUPO Initiatives (2007-2008) whose mission has been to accelerate the successful application of proteomics to the solution of important biomedical problems.

Prof. Carl Borrebaeck is chairman of the Department of Immunotechnology, Lund University and program Director of the Strategic Center for Translational Cancer Research CREATE Health (www.createhealth.lth.se). He received the first chair as professor of Immunotechnology in Scandinavia 1989. His main research interests and cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies. He is a permanent member of the Royal Swedish Academy of Engineering Sciences and deputy vice chancellor of Lund University, with a special responsibility for its innovation system. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy.
Prof. Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. He received his Doctor of Science (D.Sc.) in 1979. He is research has resulted in several spin-out companies, such as BioInvent International, Alligator Bioscience and Immunovia.

Ralph A. Bradshaw was born in Boston, Massachusetts, and received degrees from Colby College (Waterville, ME), and Duke University (Durham, NC). He was a post-doctoral fellow at Indiana University and the University of Washington and served on the faculty of Washington University School of Medicine, (St. Louis, MO) (1969-82) and the University of California, Irvine (1982 -06) (now emeritus). He is currently a professor of Pharmaceutical Chemistry and Deputy Director of the NCRR Mass Spectrometry Facility at UCSF. He has published more than 350 scientific articles, has held numerous elected offices in learned societies and has served on the editorial board of over a dozen journals. He is presently Co-editor of Molecular & Cellular Proteomics, which he helped to initiate in 2001. His research interests are in the structure and function of proteins, the regulation of N-terminal post-translational processing and the proteomics of signal transduction as induced by growth factors and their receptors.

Tiziana Bonaldi is junior group leader at the Department of Experimental Oncology of the European Institute of Oncology in Milano. She received her PhD degree in 2003 at San Raffaele Scientific Institute, in Milano. Her background is biochemistry, with expertise in chromatin proteomics, achieved as post doc at the Ludwig Maximilian University, in Munich. During her second post doc in the group of Prof. M. Mann at the MPIb, she gained expertise in global quantitative proteomics studies, carried out via the SILAC strategy.

Since her move to Milano she has been focused on the elucidation of the molecular mechanisms that regulate gene expression, using a combination of functional genomic approaches. She currently supervises a team comprised of six scientists in laboratories situated on the IFOM-IEO Campus, one of the top cancer research centres in Italy. Dr. Bonaldi is involved with several academic collaborations with groups at multiple sites, both national and international.

She is a reviewer for several academic journals and associated editor of the recently established Journal of Integrated -OMICS. Her research is sponsored by numerous national and international grants as well as she has served as reviewer for national and international funding agencies. She has been awarded the prize International Inner Wheel per la Donna 2010, for her scientific achievements.

Brian received his B.Sc. in 1969 and his B.Sc. Hons. in 1970, both from the University of Cape Town, in South Africa, and his D.Phil. in 1976 from the University of Oxford. He did postdoctoral research at the University of Manitoba and joined Rockefeller in 1979 as a research associate in Frank H. Field's laboratory. He was appointed assistant professor in 1981, associate professor in 1985 and professor in 1991. In 1995, he was named the Camille and Henry Dreyfus Professor. His awards include the 2007 HUPO Discovery Award in Proteomics Sciences, the 2002 Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry from the American Chemical Society, the 2000 Bijvoet Medal from Utrecht University and the 1998 American Association for the Advancement of Science Newcombe-Cleveland Prize. He has been awarded 22 United States patents for his inventions.

Richard Christopherson has focused on cancer research since his postdoctoral period in the USA where he was a Fellow of the Damon Runyon-Walter Winchell Cancer Fund and then a Special Fellow of the Leukemia Society of America. He is a Professor in the School of Molecular Bioscience at the University of Sydney and a Scientific Founder and Chief Scientific Officer (part-time) of the University spin-off company, Medsaic Pty Ltd (www.medsaic.com). His research has focused on elucidation of the mechanisms of action of anticancer drugs. His group determined the anti-purine mechanism of the drug methotrexate used to treat leukaemias and breast cancer. His current research includes investigation of the mechanisms of action of the anticancer drug fludarabine, by identification of proteins that are differentially abundant in drug-treated cells. A CD antibody microarray (DotScan) has been developed that provides extensive surface expression profiles (immunophenotypes or disease signatures) of leukaemias. The use of DotScan has been extended to profiling of colorectal cancers and melanoma and is being commercialised by Medsaic. Richard is Chair of the organizing committee for the translational Sydney Cancer Conference 2010 (SCC2010) to be held on July 14-16 at the University of Sydney.

Dr. Clarke received his Ph.D. degree in Mass Spectrometry and Analytical Chemistry from the University of Kent at Canterbury in England, and completed postdoctoral fellowship training in Biomedical Mass Spectrometry at the Mayo Clinic in Rochester, MN. He was a Principle Investigator at the Schering-Plough Research Institute in Kenilworth, NJ where he ran the drug discovery metabolite identification group and worked at ActivX Biosciences (a biotechnology company) as Director of Mass Spectrometry before joining Quest Diagnostics Nichols Institute.

At Nichols Dr. Clarke is the Scientific Director for the Steroids Dept. as well as running an R&D group which develops the LC-MS/MS assays utilized at the Institute. His is also the Director of Mass Spectrometry and runs multiple LC-MS/MS core depts in Quest Diagnostics. His staff is also involved in training visiting scientists from other Quest Business Units, adopting the new technology and assays developed in Dr. Clarke's laboratory.

Dr Clarke is also involved with several academic collaborations with groups at multiple sites including Cedars-Sinai, the CDC and Massachusetts General Hospital, utilizing the LC-MS/MS assays he and his group has developed to create and refine standardized reference ranges for both clinical studies and diagnostic usage.

He has published widely on his use of mass spectrometry in a variety of biological arenas, is a reviewer for several academic journals and has received multiple awards including the Michael Barber Award for Mass Spectrometry, The President's Award for Discovery from the Schering-Plough Research Institute and the Medical Innovations Award from Quest Diagnostics.

Michael Crouch is a cell biologist with 20 years experience in the study of cellular receptor signal transduction mechanisms. After completing his PhD at the University of Adelaide, Michael carried out a 3 year postdoctoral fellowship at the pharmaceutical company Burroughs Wellcome (USA). There he studied mechanisms of human platelet activation by agents such as thrombin, particularly in relation to cellular signalling. After this period he was awarded a Research Fellowship at the John Curtin School of Medical Research (JCSMR) at the Australian National University, during which time he identified mechanisms of control of cell growth by hormone receptors. This led to the award of a 5-year Wellcome Fellowship in 1992, and in 1997 he became a Fellow at the JCSMR, continuing the studies into cellular regulation. In 2001 Michael accepted a position as Principal Research Scientist at GroPep Ltd in Adelaide, and in 2002 took up the position of Director, Screening technologies at TGR BioSciences. This role was expanded in 2008 through his promotion to the position of Chief Scientific Officer at TGR, in which he oversees all of the Company's R&D.

Victor Engelhard is Professor of Microbiology at the University of Virginia. He is Leader of the Immunology and Immunotherapy Program of the University of Virginia Cancer Center, and Co-Director of the Human Immune Therapy Center. He has served on the editorial boards of the Journal of Experimental Medicine, Immunity, The Journal of Immunology, and the Immunology Section of Faculty of 1000. He has trained over 40 graduate students, postdoctoral fellows, and visiting scientists, leading to over 175 peer-reviewed and invited publications. His work has been broadly concerned with the identification and characterization of MHC-restricted peptide antigens by CD8 T lymphocytes. Current activities are primarily concerned with immune responses to antigens expressed on melanoma tumors. These include: identification of relevant antigens on human cancers that may serve as a basis for immunotherapy; evaluation of cancer vaccine strategies; and investigating the relationship between self-tolerance, autoimmunity, and immune responses to tumors.

Methods consuming small sample amounts and allow for sensitive screening of large numbers of putative biomarkers indicative of disease are required to advance biomarker discovery and validation. We present our work on multiplexed PLATM a proximity ligation assay technology were protein analytes are converted to unique DNA amplicons and subsequently detected by high throughput quantitative PCR. These multiplexed profiling panels solve many analytical problems found in biomarker verification, such as sensitivity (femto Molar), multiplexing, throughput, and sample consumption. To illustrate the capacity of our technology, we have in an EU-funded collaborative project generated data on 75 putative cancer biomarkers in 200 samples consuming only 2 uL of precious biobanked plasma in merely two weeks time.

In another incarnation of PLA performed in situ, the assay can precisely quantify proteins and protein interactions in fixed cells and tissues providing localized data visualized by fluorescence microscopy and quantified by subjective single molecule counting. The ability to study protein-protein interactions in situ using coincidence binding by pairs of primary target specific antibodies opens a new realm of biomarker opportunities based on activity of proteins rather than abundance.

Professor Jeff Gorman is Head of the Protein Discovery Centre at the Queensland Institute of Medical Research and holds adjunct Professorial appointments at the University of Queensland, the Queensland University of Technology and Griffith University.

Jeff obtained both BSc and PhD qualifications from the University of Melbourne and has close to 40 years of experience in protein research, including a Fogarty Fellowship at the US National Institutes of Health and 22 years of employment within various Divisions of the CSIRO. Throughout his career, he has established several infrastructure centres for protein analysis. He was responsible for the purchase of the first mass spectrometer in Australia solely for the purpose of protein analysis in 1984 and has made several other pioneering mass spectrometer purchases, including the first high-performance reflectron MALDI-TOF and ESI-LTQ-Orbitrap instruments in Australia.

Jeff's major personal research experiences have included enzymes of the blood coagulation system, viral protein structure and function, post-translational modification analysis and the development of specific technical approaches for the analysis of proteins. He collaborates extensively and has made substantial contributions to seminal discoveries involving regulation of oxygen sensing and other signal-activated transcriptional pathways by post-translational modifications.

His current personal research interests involve a significant international and national collaboration on the mechanisms by which the serious paediatric respiratory pathogen, respiratory syncytial virus, evades the host cell antiviral defences to cause high levels of morbidity and mortality in children. Jeff is on the Editorial Boards of several international protein science and proteomics journals, including the leading Molecular and Cellular Proteomics.

Professor Jrgen Gtz studied biochemistry at the University of Basel, and earned his PhD in immunology in the laboratory of Nobel Laureate Georges Khler at the Max-Planck-Institute in Freiburg, Germany (1989). After postdoctoral work at UCSF and the Preclinical Research Division at Novartis Ltd in Basel, he established his reputation in the Alzheimer's field as a research group leader at the University of Zrich (19942005). Since 2005, he has been Chair of Molecular Biology and Director of the Alzheimer's and Parkinson's Laboratory at the Brain and Mind Research Institute of the University of Sydney. His major research interests are in the development and analysis of transgenic mouse models for Alzheimer's disease and related dementias using the tools of functional genomics. Furthermore, he is interested in the physiological and pathological functions of the microtubule-associated protein tau.

Rudi Grimm received his Ph.D. in Biology at the University of Munich. After completing a post-doc time at the University of Freiburg/Germany and the Riken Institute in Tokyo/Japan he joined Hewlett-Packard as a senior life science application chemist in 1991. In 1998 he became the head of protein chemistry at the Munich based proteomics company Toplab. In June 1999 he joined Hexal Pharma (now part of Sandoz/Novartis) to establish the Biotech Laboratories for the development of generic recombinant protein drugs (Biosimilars). In September 2002 he re-joined Agilent Technologies as the worldwide proteomics and metabolomics market development manager. In January 2009 he became a director of science and technology at Agilent Technologies. He is author of 114 scientific publications.

William S. Hancock is Professor of Chemistry and holds the Bradstreet Chair in Bioanalytical Chemistry within the Barnett Institute of Chemical and Biological Analysis at Northeastern University, Boston, MA. Dr. Hancock received his B.Sc. in Chemistry and Biochemistry in 1966, his Ph.D. in Chemistry in 1970 and a D.Sc. in 1993 from the University of Adelaide, South Australia. He began his career in biochemistry as a postdoctoral fellow at Washington University. He then served on the academic staff at Massey University, New Zealand and was a Visiting Scientist at the Bureau of Drugs of the Food & Drug Administration in Washington, D.C. In 1985, he joined the Medicinal and Analytical Chemistry unit of Genentech in San Francisco, CA, where he rose to the position of Staff Scientist. He has held a Principal Scientist position at Hewlett Packard Laboratories and a Visiting Professorship in Chemical Engineering at Yale University. Prior to joining Northeastern University in 2002, he had served as Vice President of Proteomics at ThermoFisher Corp. in San Jose, CA. Dr. Hancock served as President of the California Separation Science Society (CASSS), based in San Francisco, CA for 10 years (1994-2004). He is the Editor-in-Chief of the ACS publication, Journal of Proteomic Research. He has published over 190 scientific publications and 7 books, holds 15 patents, and has organized and lectured in numerous international meetings. He has received many honors, including the Martin Gold Medal in Separation Science (British Chromatographic Society), Stephen dal Nogare Memorial Award in Chromatography and the ACS Award in Chromatography. Dr. Hancock's research program has focused on the application of separation science to biological problems, particularly in the area of biotechnology. His work has advanced the state of the art of HPLC as a required tool in the analysis of protein therapeutics. At the Barnett Institute, his research is focusing on cancer proteomics and the plasma proteome and is a reference laboratory for HUPO and a co-chair of the NCI Alliance of Glycan markers for the early detection of cancer. Dr. Hancock is currently serving as Pasr-President of US-HUPO (human proteome organization) and also serves on the International council.

Originally from Switzerland, Daniel gained his PhD in x-ray diffraction and advanced synchrotron techniques at King's College (London). Before joining the Australian Synchrotron, he worked at the University of London, the Synchrotron Radiation Source (UK), the European Synchrotron Radiation Facility (France) and the Advanced Photon Source (USA). After 25 years in material science - high pressure research using synchrotron radiation - Daniel switched to imaging and the medical field. Daniel is now responsible for managing the design and construction of the Imaging and Medical Beamline at the Australian Synchrotron. With a total budget of AU$24.7m, this facility, which began operating in late 2008, will enable new and advanced methods for x-ray imaging in areas as diverse as cancer detection and diagnosis, understanding biological and physiological processes, as well as characterising engineering structures. It will also enable new methods of radiotherapy for cancer treatment. Clinical research with patients is scheduled to begin in 2012.

Paul graduated from Macquarie University with a PhD degree in 1992, and embarked upon a successful research career in both industry and academia in the USA, working at The Rockefeller University in New York, University of Washington in Seattle, Genetics Institute in Boston, Torrey Mesa Research Institute in San Diego, and lastly as an Associate Professor at The University of Arizona in Tucson. In 2006 he returned to Australia to take up a New South Wales Government Biofirst fellowship. In 2008 he was appointed as an Associate Professor in the department of Chemistry and Biomolecular Sciences at Macquarie. He currently has more than 55 scientific papers published, along with four issued patents, and is a Senior Editor for Proteomics. He teaches undergraduate and postgraduates courses in proteomics and molecular biology, supervises several PhD students, and maintains a protein mass spectrometry research laboratory focusing on proteomic analysis of environmental stress.

Fuchu is a member of Chinese Academy of Sciences and the Academy of Sciences for the Developing World and Director of Chinese National Center of Biomedical Analysis and President of Institutes of Biomedical Sciences Fudan University. he is the Chair of Human Liver Proteome Project, Member of Human Proteome Organization (HUPO) Council, Senior Editor of [Proteomics], Editorial member of [Mol. Cell. Proteomics], President of Chinese Human Proteome Organization (CNHUPO), Vice President of Chinese Association of Genetics. His major fields of research are proteomics and genomics. He found several periodic phenomena of molecular evolution: Development-related evolution of cytokines; Co-evolution of cytokines and their receptors; Modulated evolution of mRNA coding regions and their non-coding regions; Slowing-down evolution of molecules during phylogeny; discovered and cloned hepatopoietin, and characterized its receptor and both autocrine and intracrine signal transduction pathways; established the comprehensive transcriptome and proteome expression profiles of human fetal liver and annotated more than 500 human novel genes and proteins. In addition, his research team identified more than ten susceptibility genes for chronic HBV infection and cancers. Recently, he proposed and initiated the Human Liver Proteome Project (HLPP), the first international life scientific project led by China, which remarkably applauded by international entities, including Nature, Science, Nature Biotechnology. He was awarded National Distinguished Young Scientists Awards, Chinese Young Scientists Award, Qiushi Award for Young Elites in Engineering, and Science and Technology Progress Prize of HO LEUNG HO LEE FOUNDATION; successively received more than 10 prizes, such as State Natural Science Award, National Award for Promotion of Science & Technology. To date, he has published more than 100 peer-reviewed papers in high impact international journals as corresponding author.

I was one of the original scientists at the Australian Proteome Analysis Facility (APAF) at Macquarie University. My core expertise is in proteomics and protein chemistry with particular expertise in sample preparation, fractionation and electrophoretic separation of complex mixtures. I have 15 years experience in the establishment and management of core facilities providing cutting edge technologies and large-project support for proteomics and systems biology. I am a co-founder of Proteome Systems Ltd and Regeneus Pty Ltd and a non-executive director of Regeneus. I have developed and commercialised technology with Bio-Rad, Sigma-Aldrich, Proteome Systems and Regeneus. My current research is in adult mesenchymal stem cells from adipose tissue.

Dr. Denis Hochstrasser is the chairman of the Genetic & Laboratory Medicine Department of the Geneva University Hospital and Vice Dean of the Faculty of Medicine, Switzerland. He is also Head of the Laboratory Medicine Division of the Geneva University Hospital, Switzerland's largest acute hospital. He still practices as a Board certified physician. At the academic level, he is full Professor both to Geneva's Department of Structure Biology & Bioinformatics, Medicine Faculty and to the School of Pharmacy, Sciences Faculty. He was one of the founders of the Swiss Institute for Bioinformatics, of the Swiss Centre for Applied Human Toxicology and also of Biobank Swiss Foundation. He is a scientific founder of Geneva Proteomics Inc, Geneva Bioinformatics SA and of Eclosion SA. His research focus on the discovery of clinical biomarkers in brain, pancreas and kidney diseases, in human toxicology and the development of proteomic & clinical chemistry related technologies.

Dr. Hoffmann received his PhD in chemistry at Universitaet des Saarlandes, Germany in 1999. He than joined the Proteomics group of Prof. Richard Simpson and held after that the position as Head of the proteomics unit at the St.Vincent's Institute both in Melbourne specialising in the use of free-flow electrophoresis in proteomics and the detection of protein phosphorylation by mass spectrometry. He played than an integral role in establishing a proteomics facility at the University Leipzig returning to Germany. In 2005, he was recruited back to Australia to establish a Proteomics Centre at the University of Adelaide. The Adelaide Proteomics Centre is equipped with the latest technology in Proteomics and provides service to academic researchers and industry. His research is focused on biomarker discovery in cancer, detection of protein phosphorylation and Tissue Imaging Mass Spectrometry. Dr. Hoffmann's group was the first in Australia to establish Tissue Imaging Mass Spectrometry.

Dr. Hood's research focuses on fundamental biology (immunity, evolution, genomics) and on bringing engineering to biology through the development of five key instruments; the DNA and protein sequencers and synthesizers and the ink-jet oligonucleotide synthesizer (making DNA arrays) for deciphering the various types of biological information (DNA, RNA, proteins and systems). In particular, the DNA sequencer has revolutionized genomics by allowing the rapid automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s and early 2000s. These instruments constitute the technological foundation for modern molecular biology and genomics.

Early in his career, he applied these technologies to the study of molecular immunology (and discovered many of the fundamental mechanisms for antibody diversity) and neurobiology (he cured the first neurological disease by gene transfer in mice). In the late 1980s he realized that to really understand immunology, it would require a systems approach, thus, he began thinking about systems biology. In 2000, he co-founded the Institute for Systems Biology in Seattle. Here he has contributed seminal papers to delineating the systems approach to biology and disease and to pioneer developing new technologies. Dr. Hood is now pioneering the idea that the systems approach to disease, the emerging technologies, and powerful new computational and mathematical tools will move medicine from its current reactive mode to a predictive, preventive, personalized and participatory mode (P4 medicine) over the next 5-20 years.

Dr. Hood was awarded the Lasker Prize in 1987, the 2002 Kyoto Prize in Advanced Technology, the 2003 LemelsonMIT Prize for Innovation and Invention, the prestigious 2004 Biotechnology Heritage Award, the 2003 Association for Molecular Pathology (AMP) Award for Excellence in Molecular Diagnostics, the 2006 Heinz Award in Technology, the 2007 Inventors Hall of Fame and in 2008, the Pittcon Heritage Award for helping to transform the biotech industry. Dr. Hood has received 17 honorary degrees and has published more than 680 peer-reviewed papers, received 26 patents, and has co-authored textbooks in biochemistry, immunology, molecular biology, and genetics, and coauthored with Dan Keveles a popular book on the human genome project - The Code of Codes. Dr. Hood has had a life-long commitment to K-12 science education and has a major effort at ISB in this regard.

Dr. Hood is one of only 7 (of more than 6000 members) scientists elected to all three US Science academies (NAS, NAE and IOM). Dr. Hood has founded more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He is currently pioneering systems medicine and the systems approach to disease and has recently cofounded the company Integrated Diagnostics - that hopefully will become a platform company for P4 medicine.

Hsuan-Cheng Huang received his B.A., M.A., and Ph.D. degrees in physics from National Taiwan University in 1992, 1994, and 1998, respectively. He was engaged in experimental high-energy physics research at Taiwan and at High Energy Accelerator Research Organization, Japan, and awarded NSC Distinguished Postdoctoral Fellowship in 2003. Encouraged by the emerging of systems biology, Dr. Huang joined National Yang-Ming University in 2004 and is currently an Associate Professor in the Institute of Biomedical Informatics and Center for Systems and Synthetic Biology. In 2007, he received the NSC Wu Ta-You Memorial Award, an honor for excellent young investigators in Taiwan. Currently he serves as an Associate Editor of BMC Systems Biology and a Board Member in Taiwan Society for Bioinformatics and Systems Biology. His research interests include computational analysis and modeling of biological networks, to unravel molecular mechanism of cancer cell response, microRNA regulation, and essential genes in microorganisms.

Professor Donald F. Hunt joined the faculty at the University of Virginia as an assistant professor in September 1968, and was promoted to associate professor and full professor in 1973 and 1978, respectively. In 1993, he was promoted to the rank of University Professor with appointments in both Chemistry and Pathology. Prior to assuming these positions, he spent a year at the Massachusetts Institute of Technology as a National Institute of Health Postdoctoral Trainee in Mass Spectrometry under the guidance of Professor Klaus Biemann. Professor Hunt obtained both his B.S. and Ph. D. (1967) degrees from the University of Massachusetts. Research for the doctoral dissertation was carried out under the direction of Professors Marvin Rausch and Peter Lillya in the area of organotransition metal chemistry. Professor Hunt was chosen as a recipient of both an NIH Fogarty Senior International Fellowship and a John Simon Guggenheim Fellowship in 1981-82. In 1990, he received the Charles H. Stone Award sponsored by the American Chemical Society. In 1992 he was named Virginia's Outstanding Scientist and also received the Pehr Edman Award for outstanding achievements in the application of mass spectrometry to the contemporary microsequence analysis of proteins. The Distinguished Contribution Award from the American Society for Mass Spectrometry was presented to Professor Hunt in 1994 for his development of electron-capture, negative-ion mass spectrometry. In 1996 he was the first recipient of the Christian B. Anfinsen Award from the Protein Society for development of new technology in the field of protein chemistry. He received the Chemical Instrumentation Award sponsored by the American Chemical Society in 1997. This award recognizes Professor Hunt for development of instrumentation capable of sequencing peptides and proteins at the attomole level. In 2000, Professor Hunt was the recipient of both the Frank F. Field and Joe L. Franklin award presented by the American Chemical Society for outstanding achievement in the field of mass spectrometry and the Thomson Medal from the International Mass Spectrometry Society. He received Distinguished Accomplishment Awards from the Human Proteome Organization (HUPO) in 2006 and the Association of Biomolecular Resource Facilities in 2007. In 2010, he received the University of Virginia Distinguished Scientist Award. Professor Hunt has over 350 scientific publications.

Dr. Hunter is the Director of Proteomics Applications at AB SCIEX. Research interests include the development of mass spectrometry workflows for quantitative proteomics. In particular, Dr Hunter has been focused on using targeted MS techniques for quantitative profiling of protein biomarkers in biological samples.

Ole N. Jensen obtained the Msc degree from the Univ. Southern Denmark in 1990 and a phd-degree in biochemistry and biophysics from Oregon State University, USA, in 1994. After 2 years of postdoctoral research at the EMBL in Heidelberg, Germany, he returned to Denmark in 1997 as an assistant professor. Since 2004, he is a professor of protein mass spectrometry. The main interest of Ole N. Jensen is quantitative mass spectrometry technology for determination of post-translational modifications involved in cellular signaling and recognition events, from the characterization of plasma membrane proteins and cell surface receptors to epigenetic mechanisms for gene regulation and maintenance of chromatin structure and function. He is also interested in the fundamentals of mass spectrometry techniques for characterization of proteins and peptides, including advanced ion dissociation techniques, multistage mass spectrometry and ion mobility spectrometry. Ole N. Jensen has coauthored more than 175 research articles and presented lectures at many international meetings. More details can be found at www.protein.sdu.dk.

Hsueh-Fen Juan is a Professor in Department of Life Science, Institute of Molecular and Cellular Biology, and Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University (NTU). She received her Ph.D. in Biochemical Sciences in 1999 from NTU and worked as a research scientist in Japan International Research Center for Agricultural Sciences. She was one of the founders and the Deputy Director of Center for Systems Biology and Bioinformatics of NTU and organized several international systems biology and bioinformatics symposiums. In 2008, she was awarded as Taiwan's Ten Outstanding Young Persons. She currently serves as a Board Member in the Taiwan Society for Biochemistry and Molecular Biology, Taiwan Proteomics Society, Taiwan Bioinformatics and Systems Biology Society. Her research focuses on cancer systems biology, integrating transcriptomics, proteomics and bioinformatics for biomarker and drug discovery.

Peter Karuso is one of the pioneers of reverse chemical proteomics and the proteomic application of natural products. He is known for developing methods that have found applications in proteomics such as the popular fluorescent stain Deep Purple used in 1D and 2D gel electrophoresis. More recently, Peter and his team have been combining organic synthesis with phage display to develop new methods for rapidly determining the protein-binding partners for small molecules such as natural products and drugs. This reverse chemical proteomics method is expected to lead to the rapid generation of interaction maps for small molecules and uncover new signaling pathways related to disease states and provide new druggable leads for Pharma. Peter is a member of several editorial boards in the fields of proteomics and organic chemistry. Peter obtained his Ph.D. in Chemistry at the University of Sydney in 1985 and co-founded the biotech company Fluorotechnics in 2004 for which he received an Innovation Award from Macquarie University in 2007. Peter is also a recipient of the Royal Australian Chemical Institute's Archibald Oll Prize and a Fellow of the RACI.

Associate Professor Maria Kavallaris is Head of the Pharmacoproteomics Program at the Children's Cancer Institute Australia. Her research contributions are internationally regarded and include identifying mechanisms of action and resistance to anticancer drugs that target cell division;discovering new cytoskeleton interactions in cell division; and the development of less toxic cancer therapies using nanotechnology. Her proteomic studies have led to the identification of novel mechanisms of resistance to anticancer agents that target key proteins associated withcell division in cancer.

MariaKavallaris is anNHMRC Senior Research Fellow and holds a conjoint appointment in the Faculty of Medicine, University of New South Wales. Her research contributions have been recognized bya number of awards and prizesincluding an International Agency for Research on Cancer Fellowship, an AACR Women in Cancer Research Award, a Young Tall Poppy Award, and an Australian Museum Eureka Prize.She has authored over 65 publications including recent reviews in Nature Reviews Cancer and Nature Reviews Clinical Oncology.

Carlitto's group focuses on the development of analytical tools in two areas - nutrition and diseases. He is developing mass spectrometry based tools for the discovery of markers for cancer including ovarian, breast, and prostate. His approach is to examine the post-translational modification of proteins particularly in the forms of glycosylation. Carlitto is pioneering the glycomics approach for the early diagnosis of cancer and developing the infrastructure in terms of analytical tools and bioinformatics for glycan based disease marker discovery. He is are also deconstructing the components of mammalian milk to determine what in milk makes it the perfect food for the infant.

Dr. Bonghee Lee received his DVM and PhD from Seoul National University College of Veterinary Medicine. He is currently the Director of the Center for Genomics and Proteomics and the Stem Cell Core Facility at Gachon University of Medicine and Science. In addition to his responsibilities at Gachon University, Dr. Bonghee Lee is the co-chair of HUPO's Human Stem Cell Proteome Initiative, Vice-president of the Korean Human Proteome Organization and a board member of the Korean Society for Stem Cell Research. Dr. Lee is also a member of Science Advisory Board for Regenerative Medicine Division of Sigma-Aldrich. His research interests include functional proteomics and systems biology for stem cell and cancer biology.

Dr Rune Linding lead the Cellular & Molecular Logic Team at The Institute of Cancer Research (ICR) in London. He performed his graduate work at the EMBL (Germany), where he pioneered computational signalling biology by developing popular tools like ELM, GlobPlot and DisEMBL for analysing post-translational modifications and intrinsic protein disorder. Dr Linding was Human Frontiers Science Program Postdoctoral Research Fellow jointly with Profs Tony Pawson and Mike Yaffe at Samuel Lunenfeld Research Institute (Canada) and Massachusetts Institute of Technology (USA), respectively. His postdoctoral work on the cellular phosphorylation networks and development of the NetworKIN algorithm pioneered Integrative Network Biology and led to the discovery of the importance of contextual kinase specificity. At ICR his lab unravelled systems-level models of JNK and EphR kinase networks, demonstrated a link between specificity and oncogenecity of kinases and introduced the concept of Network Medicine. Dr Linding leads the NetPhorest community resource and have pioneered comparative phospho-proteomics and evolutionary studies of signalling networks. Dr Linding founded the Integrative Network Biology initiative (INBi) at the ICR which aims to block cancer metastasis by integration of large-scale, high-dimensional quantitative genomic, proteomic and phenotypic data. The long-term focus of his research group is on studying cellular signal processing and decision making.

Susanna Lindman is currently an R&D senior scientist with over 6 years at GE Healthcare and a background in protein microfluidics and medicinal chemistry. She is a resident technical expert in the area of protein research, covering the workflows from sample preparation to protein analysis and purification. Susanna holds a Ph.D. in Medicinal Chemistry in the field of peptidomimetics.

Dr. Lopez is currently Director of the ThermoFisher BRIMS (Biomarker Research Initiatives in Mass Spectrometry) Center in Cambridge, MA where she is in charge of developing comprehensive, MS-based workflows from sample preparation to bioinformatic analysis for robust biomarker discovery and clinical validation. Previously, Dr. Lopez held positions as Strategic Collaborations Leader and Analytical Proteomics Business Leader at PerkinElmer Life and Analytical Sciences in Waltham, MA and Executive Vice President of Proteomics Research and Development at Proteome Systems. Since 1989, Dr. Lopez has worked in the fields of proteomics, electrophoresis and protein chemistry and served as Vice President of Proteomics R&D at Genomic Solutions Inc., Director of Chromatography Applications, PerSeptive BioSystems and Senior Scientist, Millipore Corp. Dr. Lopez was a Post Doctoral NIH Fellow at MIT and received her Ph.D. in Botany from the University of Massachusetts, Amherst, MA in 1985. Dr. Lopez has published extensively in the Proteomics field. And serves on the SAB of the Buck Institute for Age Research in Novato, CA.

Professor Colin Masters is a leader in research into Alzheimer's disease and other neurodegenerative disease, including Creutzfeldt-Jakob and other prion diseases, and his work over the last 35 years is widely acknowledged as having had a major influence on Alzheimer's disease research world-wide. This work has led to the continued development of novel drugs and therapeutic strategies to treat these diseases.
Professor Masters is currently the Director of the Mental Health Research Institute, and Laureate Professor at the University of Melbourne. He is the Chair of the NHMRC's Transmissible Spongiform Encephalopathies Advisory Committee, a consultant in neuropathology at the Royal Melbourne Hospital and a scientific advisor to Neurosciences Australia. His achievements have been recognised by the receipt of many international awards - including the King Faisal International Prize in Medicine (1996), the Grand Hamdan International Award for Medical Sciences (2006) and the Victoria Prize from the Minister for Innovation (2007).

Harvey Millar did his PhD (1997) in plant biochemistry and molecular biology at The Australian National University, Canberra. He has previously held fellowships in the UK and Australia (HFSPO, ARC APD, ARC QEII) and is currently an ARC Australian Professorial Fellow at The University of Western Australia. He has been awarded the Peter Goldacre Medal from the Australian Society for Plant Scientists (ASPS 2003), the Premier's Prize for Early Career Achievement in Science for Western Australia (2003), and the Science Minister's Prize for Australian Life Scientist of the Year, one of the Prime Minister's Science Prizes (2005). He serves on the Editorial Boards of The Journal of Biological Chemistry, Journal of Proteomics, Plant Methods and The Arabidopsis Book. His research is focused on understanding the role mitochondria play in the primary carbon and nitrogen metabolism of plants and their response to oxidative stress.

Molloy's research focuses on the development and implementation of quantitative proteomic methods for biomedical research. He obtained his PhD from Macquarie University, Sydney, under the mentorship of Keith Williams, conducted post-doctoral training with Philip Andrews at the University of Michigan Medical School and worked with Ruth vanBogelen in the proteomics R & D group at Pfizer Inc. Currently, he is Associate Professor and Director of APAF at Macquarie University. Amongst Molloy's interests have been the rigorous examination of quantitative techniques for comparative proteomics including both gel and non-gel based analyses. His recent research efforts have focused on colorectal cancer and the use of iTRAQ and selected reaction monitoring mass spectrometry methods to identify prognostic and predictive biomarkers. He has active research programs using quantitative proteomic analyses in the area of TGF-beta cancer biology, chemical proteomics and translational colorectal cancer research.

Robert Moritz, a native of Melbourne, is the current head of Proteomics at the Institute for Systems Biology in Seattle, Washington. Robert has pioneered many micro techniques in protein chemistry during the 25 years he spent at the Ludwig Institute For Cancer Research in Melbourne before relocating to Seattle and continues this effort in systems biology at the ISB. His research efforts include proteomics tools development and applying these to understand cellular biochemistry and indicators of the aberrant status of cells. Robert conceived the Australian Proteomics Computational Facility in 2006, and remains as the Director of this full service mass spectrometry web-based data server. He has co-founded both the Lorne Proteomics Symposium and the Australasian Proteomics Society, now in its 16th year. Robert received his PhD at the University of Melbourne and has authored more than 140 publications.

My long term scientific research has specialised in the development of new techniques (e.g. micropreparative HPLC, biosensor analysis, proteomics) for the micro-isolation, purification, characterisation and analysis of protein growth factors, their receptors and associated signalling molecules with the aim of understanding the role of these molecules in neoplasia (in particular colorectal cancer (CRC)). Many of these studies have been aimed at the discovery of potential CRC biomarkers for early detection and surveillance. To this end we are currently investigating the field of Faecal Proteomics, and the role of quantitative mass spectrometry (using the technique of multiple reaction monitoring (MRM)) for the development and validation of sensitive and specific multiplexed assays for use with panels of CRC biomarkers. This platform technology can be readily translated to other cancers, or other pathologies (e.g. cardiovascular disease, diabetes, neuropathology).

He is Vice-President of HUPO, Chair of HUPO Initiatives, Co-Chair of the Plasma Proteome Project, and president of USHUPO. His research is focused on cancer proteomics, splice isoforms, and biomedical informatics. Previously, he was professor medicine and dean of public health at the University of Washington from 1982-1997; associate director of the Office of Science and Technology Policy and the Office of Management and Budget for President Carter; and Howard Hughes Investigator. He is a member of the Institute of Medicine/National Academy of Sciences, past president of the AAAS, and a director of Amgen Inc. He is author of 473 research papers and scientific reviews and author/editor of 18 books (www.med.umich.edu/omenn). He earned B.A. at Princeton, M.D. at Harvard, and PhD in Genetics at University of Washington.

Dr. Ron Orlando has over twenty-five years experience with the analysis of biological molecules with mass spectrometry. He specializes in the analysis of proteins and their post-translational modifications, particularly glycosylation. Work in the Orlando lab is currently focused on the development of mass spectrometry based techniques for: (1) the high throughput analysis of glycoproteins and carbohydrates from complex biological samples, (2) the structural characterization of complex biologically active glycoproteins and protein carbohydrate interactions, (3) analyzing protein expression in numerous parasites including the ones that cause African Sleeping Sickness and Chagas' disease. Ron has authored or co-authored over 100 publications in peer reviewed journals; routinely serves on National Institutes of Health review panels; presented over 100 invited lectures on protein analysis with mass spectrometry.

Dr. Overall is a Professor, and Tier 1 Canada Research Chair in Metalloproteinase Proteomics and Systems Biology, at the University of British Columbia Center for Blood Research. He was the 2002 CIHR Scientist of the Year, Chaired the 2003 MMP and the 2010 Proteolytic Enzmes and Inhibitors Gordon Research Conferences, and was awarded the University of British Columbia Killam Senior Researcher Award (Science) 2005. He was a visiting scientist at British Biotech, Oxford (1997-1998) and at the Centre for Proteomic Chemistry, Novartis, Switzerland (2004, 2008). His research interests are in positional proteomics for N- and C-terminome analysis, protease proteomics (degradomics) and breast cancer metastasis. He is the pioneer of degradomics, with Nature Review Papers on this and protease genomics, drug target validation, MMP therapeutics, and substrate discovery. He has pioneered numerous approaches to decipher the protease and substrate degradomes by quantitative proteomics and N-terminome analysis in cell-based systems and in animal models.

Nicki has had an extensive and varied career in biochemical research in both Chemistry and Biological Sciences. She was part of the team that established the Australian Proteome Analysis Facility (APAF) at Macquarie University in 1996 which was at the forefront of the emergence of proteomics research. She left the University in 1999 to co-found Proteome Systems Limited, an Australian biotechnology company specialising in the development and application of proteomic and glycomic technology for diagnostics discovery, in which her group developed a platform of glycoanalytical technology and informatics tools. She now finds herself back at Macquarie University as a Professor and Director of the Centre of Biomolecular Frontiers, Department of Chemistry and Biomolecular Sciences. Her research interests now are in the structure and function of glycans, particularly in their role in cancer and microbial pathogenesis.

Nicki has published extensively on glycomics research, is a senior editor of Proteomics, on the Scientific Advisory Board of two biotechnology companies and the Advisory Committee of the Human Disease Glycomics/Proteomics Initiative (HGPI) of HUPO. She has also succeeded in producing 3 reasonably well-balanced children.

Dr. Paik is a Professor at the Departments of Biochemistry and Biomedical Science and Director of YPRC/BPRC in Yonsei University, Seoul, Korea. He is currently serving as President of both HUPO and AOHUPO and Senior Editor for PROTEOMICS and PROTEOMICS:Clinical Proteomics. He is one of the founding members of both KHUPO and AOHUPO. His research interests focus on the discovery of biomarker for liver cancer, HPP, glycoproteomics and proteogenomics of aging in C. elegans. In 1999, he established YPRC, a flagship center in Korea, which serves as a central provider for education, training, and technical services in the field of proteomics throughout the nation. Before he joined Yonsei University, he had worked as Associate Professor of Biochemistry at Hanyang University, Korea (89-93) and Staff Research Investigator at Gladstone Institutes at UCSF, USA (83-89). He earned his Ph.D. in Biochemistry from the University of Missouri-Columbia, USA, in 1983.

Akhilesh Pandey, M.D., Ph.D. is currently an Associate Professor at the Institute of Genetic Medicine and the Departments of Biological Chemistry, Oncology and Pathology at the Johns Hopkins School of Medicine. He obtained his medical degree from Armed Forces Medical College, Pune and completed his residency in Pathology at the Brigham and Women's Hospital, Harvard Medical School. He obtained his Ph.D. in the laboratory of Vishva Dixit at the University of Michigan, Ann Arbor in 1995 and carried out his Postdoctoral work in the laboratory of Harvey Lodish at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology from 1996-1999. He was a Visiting Scientist with Matthias Mann at the University of Southern Denmark from 1999-2002 before joining Johns Hopkins in 2002.

Dr. Pandey has received numerous prestigious awards including the Experimental Pathologist-In-Training Award by the American Society for Investigative Pathology, Howard Temin Award from the National Cancer Institute, Sidney Kimmel Scholar Award by the Sidney Kimmel Foundation for Cancer Research and the Beckman Young Investigator Award by Arnold and Mabel Beckman Foundation. He has recently received the Era of Hope Scholar Award by the Department of Defense which is "intended for exceptionally talented, early-career scientists who have demonstrated that they are the best and the brightest in their field(s) through extraordinary creativity, vision, and productivity, and who have shown a strong potential for leadership in the breast cancer community as well as a vision for the eradication of breast cancer." He is a past Editorial Board member of Genome Research and currently serves as an Editorial Board member of Molecular and Cellular Proteomics, Journal of Proteome Research, Proteomics, Clinical Proteomics and DNA Research and as an Associate Editor of BMC Bioinformatics. He is also the Founder and Director of the Institute of Bioinformatics, a non-profit research institute in Bangalore, India.

Associate Professor Anthony W Purcell is a senior research fellow in the Department of Biochemistry and Molecular Biology and a laboratory head at the Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne. His research interests include mass spectometry, proteomics and the biochemical definition of peptides recognised by the immune system, with a particular emphasis on the role of post-translationally modified antigens and their role in health and disease. Dr Purcell also leads a peptide based vaccine program that aims to design highly specific and stable peptide like lead compounds for inclusion in anti-tumor immunotherapies.

In 2008, Dr Purcell was awarded a NH&MRC Senior Research Fellowship and the Roche Medal from the Australian Society for Biochemistry and Molecular Biology. He was the recipient of the Allan Stephens Ward from Arthritis Australia and a Grimwade Research Fellowship in 2005.

Mark Raftery obtained a PhD in organic chemistry and mass spectrometry from the University of Adelaide and has since focused on all aspects of biological mass spectrometry including chromatographic separations and analysis of proteins/peptides, and the analysis of small molecule by mass spectrometry. These efforts have lead to the completion of a number of successful projects and publications. His research interest range from high through-put mass spectrometry based proteomics to careful elucidation of novel post-translational modifications. He also facilitates access to sophisticated mass spectrometry instrumentation and techniques through his current position as Acting Director of the Bioanalytical mass spectrometry facility at University of New South Wales.

Prof. Pier Giorgio Righetti (Politecnico of Milano) studied chemistry at the University of Pavia and spent 4 years as a post doc. at MIT and Harvard Medical School. He is in the Editorial Board of Electrophoresis, J. Chromatography A, J of Proteomics, Proteomics, BioTechniques. He has developed methodologies in Biochemistry and Proteome analysis (isoelectric focusing in immobilized pH gradients, multicompartment electrolyzers with isoelectric membranes, membrane-trapped enzyme reactors, temperature-programmed capillary electrophoresis), and in chemistry of monomers and polymers (Immobilines and N-substituted polyacrylamides). He has developed a combinatorial ligand library of hexapeptides to search for low-abundance proteome and biomarkers in human urines, sera and cerebrospinal fluid. He has written Proteomics Today (Hamdan, M., Righetti, P.G., Wiley, Hoboken, 2005). He has won the CaSSS (California Separation Science Society) and the Cs. Horvath awards. On 540 articles reviewed by Scopus, Righetti scores 10.000 citations, with an average of 19 citations/article and with a H-index of 48.

Dr. Roessner has obtained her PhD in Biochemistry at the MPI for Molecular Plant Physiology in Germany, where she developed novel GC-MS methods to analyse metabolites in plants. Together with the application of sophisticated data mining the field of metabolomics was born and is today an important tool in biological sciences, systems biology and biomarker discovery. In 2003 she moved to Australia where she established a GC-MS and LC-MS based metabolomics platform as part of the ACPFG. Since 2007 Dr. Roessner has been involved in the setup of Metabolomics Australia (MA), an NCRIS 5.1 investment through Bioplatforms Australia Ltd and now leads the MA node at the School of Botany, The University of Melbourne.

Jan E Schnitzer, MD, is Director of the Proteogenomics Research Institute for Systems Medicine (PRISM) in San Diego, CA. Dr. Schnitzer received a BSE in Chemical Engineering from Princeton University and an MD from the University of Pittsburgh. He did postdoctoral training at Yale University School of Medicine in Cell Biology. He was an Assistant Professor at UCSD, an Associate Professor of Pathology at Harvard Medical School and Beth Israel Hospital, and Scientific Director at the Sidney Kimmel Cancer Center before founding PRISM.

Dr. Schnitzer's research has focused on characterizing the molecular and functional diversity of the vascular endothelium which lines all blood vessels and plays an essential role in vascular permeability and organ homeostasis. His lab was the first to isolate endothelial plasma membranes and caveolae directly from normal and tumor tissues and map the proteins present in these subcellular domains. He discovered that caveolae at the surface of endothelial cells have specialized transport machinery to actively pump select proteins out of the blood, across the cell, and into the tissue, even against a concentration gradient.

His current research integrates proteomic, antibody, bioinformatic, systems, and imaging technologies to map accessible targets and characterize the in vivo function of the vascular endothelia and caveolae in health and disease. This work has started to provide basic understanding of the vital blood-tissue interface, to identify key expression changes during disease progression that can act as biomarkers or therapeutic targets, and to create novel drug delivery platforms that can target and penetrate a specific tissue in vivo. Distinct antibodies have been generated that, upon intravenous injection, are pumped rapidly and specifically into lung or tumors. These antibodies have been used to target drugs, nanoparticles, and imaging probes and to successfully treat cancer and lung disease.

Professor Simpson received his PhD in biochemistry and chemistry at Melbourne University, Australia in 1974. After post-doctoral studies at the NIH, Bethesda, Maryland, he returned to Australia as a Research Fellow at St.Vincent's Institute of Medical Research, Melbourne. He is currently Head of the Protoemics Research Laboratory of the Ludwig Institute for Cancer Research, a Research Professor at the University of Melbourne and Adjunct Professor at Yonsei University, Korea. He is Chairperson of the Human Proteome Organization (HUPO) Finance Committee and Treasurer of HUPO. On a national level, Professor Simpson is President of the Australasian Proteomics Society (APS) and an Executive Committee Member, Australian Proteomics Computational Facility (APCF)

Professor Ian Smith is Pro-Vice Chancellor Research and Research Infrastructure at Monash University. Ian is also the Director of the Victorian node of the NCRIS funded Proteomics Australia Consortium. Ian's research applies proteomics technologies to study the proteases involved in the generation and metabolism of peptide regulators of both brain and cardiovascular function. This research is well-recognised internationally; for example, in the last five years he has had 14 invitations to speak at major international meetings, many as a plenary speaker. He serves on seven international editorial boards and has published over 200 papers. Ian collaborates and consults widely with pharmaceutical and biotechnology industries and has filed many patents. He is a co-founder of a proteomics-based, publicly listed, biotechnology company and sits on many national and international boards and committees. Over the years he has held office bearing positions in a many national and international societies and has been actively involved in the organisation of numerous scientific meetings.

Dr. Srivastava is chief of the Cancer Biomarkers Research Group in the Division of Cancer Prevention, National Cancer Institute. Dr. Srivastava has received several honors and awards and is a member of a number of scientific committees. In 1995, he was elected to the American joint Committee on Cancer (AJCC) which is responsible for developing staging criteria for cancers for worldwide use and currently serves on the AJCC Executive Committee. Dr. Srivastava has played a pivotal role in the development of the ABethesda Guidelines@ for diagnosing hereditary non-polyposis colorectal cancer and in the development of International Criteria for screening microsatellite instability in cancer patients. He has played a key role in conceptualizing and implementing informatics infrastructure for the National Cancer Institute's Early Detection Research Network and the Alliance of Glycobiologists for the Detection and Early Cancer and Cancer Risk. He has successfully chaired workshop, conferences, working groups, and other NIH wide committees and published more than 170 research papers, review articles and commentaries in peer reviewed journals. He has edited several monographs and book chapters. Recently, he has edited two books: AEarly Detection of Cancer: Molecular Markers, which has published by the Futura Publishing Company in 1995. He is also Editor-in Chief of the journal, Disease Markers and Cancer Biomarkers published by the IOS Press. Recently, he edited a book on Informatics in Proteomics published in June 2005 by Francis and Taylor, New York.

Detlev graduated from the Univ of Konstanz (Germany) with a thesis on Immunoaffinity mass spectrometry in 1991. He spent a year with Prof. Fred McLafferty at Cornell (USA) working on gas phase protein structures and is now Dept Head for MALDI Applications R&D at Bruker Daltonics. His current research interests include developing biomarker discovery platforms enploying label and label-free quantitative proteomics and tissue imaging, and top-down protein sequencing.

Tine Thingholm has worked with phosphoproteins for the last 9 years. In 2003, she joined the Protein Research Group at the University of Southern Denmark to work in the area of phosphoproteomics. In this particular area of research Tine completed a M.Sc. and Ph.D under the supervision of Professor Ole Nrregaard Jensen. Tine has worked on the development of new and efficient methods within the area of phosphoproteomics. One method is the optimized protocol for titanium dioxide chromatography which is now used by most phosphoproteomics research groups. In 2008, she published the SIMAC method which is an entire new strategy for the selective enrichment and separation of mono- and multi-phosphorylated peptides prior to mass spectrometric analysis. Tine is currently working as a Postdoctoral Fellow at The Molecular Endocrinology Unit at Odense University Hospital in Denmark where she implement these strategies for the characterization of insulin resistance in type 2 diabetic patients.

Mathias is a member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science (KVA), the European Molecular Biology Organization (EMBO) and member of the Human Proteome Organization (HUPO) Council and was chairman of the Swedish Biochemical and Molecular Biology Society (SFMB) from 1994 to 1999. Mathias has more than 300 publications in bioscience with the focus on the development and use of affinity reagents in biotechnology and biomedicine. Mathias cloned and characterized staphylococcal protein A and used it as an affinity tag for purification of proteins. In the late eighties, Mathias published use of magnetic microspheres with streptavidin for automated solid phase applications. Such laboratory systems based on streptavidin beads are at present frequently used both in research and diagnostics. In the 90:ies, his group described a new principle for affinity reagents (Affibodies). He also developed a new strategy for DNA analysis called pyrosequencing. At present, Mathias runs the Human Protein Atlas portal (www.proteinatlas.org) that contains more than 7 million high-resolution images representing 6,800 human proteins. He has founded several companies and received numerous awards.

Tony Whetton is Professor of Cancer Cell Biology and Head, School of Cancer and Enabling Sciences, University of Manchester, UK. He is also Section Head for Infrastructure and Technology in the Manchester Academic Health Science Centre.

Professor James Whisstock is an ARC Federation Fellow, leader of the NHMRC Program grant on Protease systems biology and chief investigator on the ARC Centre of Excellence in Structural and Functional Microbial Genomics. James has published over 130 papers in the fields of proteases, protease inhibitors, structural biology and Bioinformatics. James's research includes understanding how proteins control medically important processes such as blood coagulation, neurotransmission and the immune response to bacterial and viral infection. Most recently, using structural and computational biology James has demonstrated that key human immune defense molecules such as perforin and complement C9 belong to an ancient family of toxins deployed by pathogenic bacteria to destroy tissue. These data, published in Science, suggest a mechanism for perforin and complement pore formation and provide a route to control the unwanted activity of these molecules in human diseases such as transplant rejection and diabetes.

Christine Wu received her B.S. in Biochemistry from UCLA and her Ph.D. in Cell Biology from the University of Colorado. She did her postdoctoral training with Dr. John Yates at the Scripps Research Institute in La Jolla and then joined the faculty in the Pharmacology Department at the University of Colorado School of Medicine in 2004 as an Assistant Professor. Chris recently moved her lab to the University of Pittsburgh School of Medicine where she is currently an Associate Professor in the Department of Cell Biology. Her research focus continues to be the development of proteomic technology for the analysis of integral membrane proteins in the context of complex biological samples.